We now seek to apply our v/acc approach – vaccine accelerationism – to HCV, Strep A, and TB, three pathogens which collectively kill ~2 million people a year, and for which there are no existing effective vaccines. More in the video below: (4/4)

youtu.be/OXxo49WrODQ

Our soon-to-be open sourced COVID-19 vaccine funded by Vitalik & Balvi is designed to protect against both current & future variants of SARS-CoV-2, aligning with the goals of d/acc. It will enter a Phase I trial in the US conducted & sponsored by NIAID (@niaidnews.bsky.social) in 2025. (3/4)

Vitalik, via his biosecurity and public health organization Balvi, was the first to believe in our vision of leveraging the 10x cost & speed advantages of doing R&D in India to develop fundamentally better, broader, safer, and more transparent vaccines, and is our largest funder. (2/4)